Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Century Therapeutics (IPSC) Amortizatization of Intangibles (2024 - 2025)

Century Therapeutics (IPSC) has disclosed Amortizatization of Intangibles for 2 consecutive years, with $349000.0 as the latest value for Q4 2025.

Quarterly Amortizatization of Intangibles fell 66.21% to $349000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, down 51.02% year-over-year, with the annual reading at $2.4 million for FY2025, 51.02% down from the prior year.
Amortizatization of Intangibles for Q4 2025 was $349000.0 at Century Therapeutics, down from $507000.0 in the prior quarter.
The five-year high for Amortizatization of Intangibles was $1.3 million in Q2 2024, with the low at $349000.0 in Q4 2025.